Journal Title：Oncoimmunology

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.

OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.

腫瘤免疫學(xué)涉及自然或治療誘導(dǎo)的癌癥識(shí)別，以及癌變、炎癥和免疫監(jiān)視之間錯(cuò)綜復(fù)雜的相互作用。我們現(xiàn)在創(chuàng)建了一本新的、備受矚目的期刊《腫瘤免疫學(xué)》，專門研究腫瘤免疫學(xué)。最近的進(jìn)展使得抗癌免疫療法首次獲得臨床證明（并獲得 FDA 批準(zhǔn)）。人們也越來越懷疑——出乎意料的是——許多當(dāng)前使用的化療藥物的療效取決于免疫效應(yīng)物的積極作用。打個(gè)比方，應(yīng)用成功的化療（或放射治療）方案的腫瘤學(xué)家利用了免疫系統(tǒng)識(shí)別腫瘤特異性或腫瘤相關(guān)抗原的能力，并控制了癌癥（干細(xì)胞）細(xì)胞的生長，卻沒有意識(shí)到有無形的幫助之手。因此，免疫生物標(biāo)志物在確定癌癥預(yù)后和預(yù)測化療療效方面變得越來越重要。還有強(qiáng)有力的理由支持將傳統(tǒng)抗癌療法與免疫療法相結(jié)合。

OncoImmunology 將接受腫瘤免疫學(xué)基礎(chǔ)、轉(zhuǎn)化和臨床領(lǐng)域的高調(diào)投稿。歡迎提交涉及實(shí)體或血液癌癥、炎癥、先天和獲得性免疫反應(yīng)的投稿。

Oncoimmunology創(chuàng)刊于2012年，由Landes Bioscience出版商出版，收稿方向涵蓋ONCOLOGYIMMUNOLOGY - IMMUNOLOGY全領(lǐng)域，此刊是該細(xì)分領(lǐng)域中屬于非常不錯(cuò)的SCI期刊，在行業(yè)細(xì)分領(lǐng)域中學(xué)術(shù)影響力較大，專業(yè)度認(rèn)可很高，所以對原創(chuàng)文章要求創(chuàng)新性較高，如果您的文章質(zhì)量很高，可以嘗試。平均審稿速度 24 Weeks ，影響因子指數(shù)6.5，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。